All Articles
The Bottom Line... Sarbanes-Oxley Affects Private Companies And Nonprofit Organizations, Too
When Congress enacted the legislation known as the Sarbanes-Oxley Act in 2002, it fundamentally changed the way public companies operate. The law mandated sweeping changes in accounting and corporate governance matters as well as in reporting requirements to the Securities and Exchange Commission...
Read MoreUnderstanding How The Principle Of Community Exhaustion Affects Your IP
What Exactly Is "The PrincipleOf Exhaustion?" The Principle of Exhaustion is a fundamental limitation on intellectual property rights (IPRs), the legally created rights of the intellectual property holder that attach with a particular form of intellectual property (IP), such as patents, trademarks...
Read MoreThinking Outside The Box To Achieve Diversity
Editor: What are law firms doing today to expand diversity? Davies: Law firms are finally realizing that good intentions are not enough. We all need to be proactive in expanding outreach, both to encourage diverse students to join the legal profession and to make ourselves more accessible to...
Read MorePhiladelphia: The Right Business Incentives And Legal Community Create A Dynamic Commercial Center Cozen O'Connor (215) 665-2000
Editor: Based in Philadelphia, your firm has expanded to 20 offices throughout the U.S., an international office in London and an affiliate office in Toronto.As the founder and chairman of this successful enterprise, how would you describe Philadelphia's economic and business climate? Cozen:...
Read MoreU.S. Sentencing Commission Amends Corporate Guidelines - What Do The Changes Mean For You?
Editor: So, what has changed lately regarding corporate governance? Boss: In April, the U.S. Sentencing Commission promulgated revised sentencing guidelines for corporations. This is the first change to these guidelines since they were enacted in 1991. These guidelines not only serve as the basis...
Read MoreEmerging Growth In The Biotechnology And Pharmaceutical Industries
Editor: What is the current climate in the biotech/pharma industries as far as capital? Heller: Over the last year, we have seen more deal flow and venture funding. I attribute this to more optimism in the public markets, venture funds wanting to get off the sidelines as they have been for a couple...
Read More